 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
2012 Sees Rise of Targeted Proteomics and DIA-MS, Continued Clinical Push by Big Industry Players
January 04, 2013
2012 Sees Rise of Targeted Proteomics and DIA-MS, Continued Clinical Push by Big Industry Players
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BRIMS-Led Study Suggests Clinical Viability of SRM-MS, Vendors' Role in Clinical Proteomics Process
June 8, 2012 / ProteoMonitor - Targeted Mass Spec Slowly but Steadily Moving Toward Broader Commercial, Clinical Adoption
September 21, 2012 / ProteoMonitor - GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor - Caprion Leading $21M Clinical Biomarker and Personalized Medicine Development Project
February 22, 2013 / ProteoMonitor - Immundiagnostik Deal Offers Thermo Fisher Chance to Highlight Immunoaffinity Mass Spec Workflows
October 26, 2012 / ProteoMonitor